復星國際(00656.HK)與花旗簽訂戰略合作協議
復星國際(00656.HK)公布,與花旗簽訂戰略合作協議,雙方承諾將合作為復星國際及其子公司的未來發展戰略提供支持。
復星國際首席執行官汪群斌表示,雙方合作源於花旗提供的一系列併購顧問與諮詢服務,目前合作領域已經覆蓋「健康、快樂、富足」三大核心板塊業務。通過此次合作,復星可借助花旗全球的網絡和資源,持續深化和加快集團的全球增長戰略,尤其是強化並支持集團的核心產業運營能力,推動科技引領的發展策略,並進一步夯實對持續創新的投入力度。
花旗亞太區銀行、資本市場及戰略顧問部負責人Jan Metzger則指,將依託花旗領先的全球網絡佈局,為復星在「健康、快樂、富足」三大領域的戰略發展提供全面的金融服務支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.